Boehringer bags first biosimilar approval in the EU

Boehringer Ingelheim has won its first biosimilar approval in Europe with authorisation of Cyltezo for a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

• Source: Pharmatimes
• 594
• November 16, 2017